Cover Image
市場調查報告書

Inotek Pharmaceuticals Corporation - 產品平台檢討

Inotek Pharmaceuticals Corporation - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 192660
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Inotek Pharmaceuticals Corporation - 產品平台檢討 Inotek Pharmaceuticals Corporation - Product Pipeline Review - 2014
出版日期: 2014年09月10日 內容資訊: 英文 27 Pages
簡介

Inotek Pharmaceuticals Corporation的產品平台分析

Inotek Pharmaceuticals Corporation 是開發青光眼和顯影劑腎臟病等治療藥的製藥公司。特別致力於開發治療眼睛的重大疾病藥物候補,開發可滿足醫療需求具有新作用機制的分子。

本報告提供Inotek Pharmaceuticals Corporation的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Inotek Pharmaceuticals Corporation的基本資料

  • Inotek Pharmaceuticals Corporation概要
  • 主要資訊
  • 企業資料

Inotek Pharmaceuticals Corporation:R&D概要

  • 主要的治療範圍

Inotek Pharmaceuticals Corporation:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Inotek Pharmaceuticals Corporation:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Inotek Pharmaceuticals Corporation:藥物簡介

  • trabodenoson
  • INO-4885
  • INO-741
  • INO-763
  • Small Molecules to Inhibit PARP

Inotek Pharmaceuticals Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Inotek Pharmaceuticals Corporation:最近的開發平台趨勢

Inotek Pharmaceuticals Corporation:暫停中的計劃

Inotek Pharmaceuticals Corporation:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • PJ-34

Inotek Pharmaceuticals Corporation:總公司和子公司的所在地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06387CDB

Summary

Global Markets Direct's, 'Inotek Pharmaceuticals Corporation - Product Pipeline Review - 2014', provides an overview of the Inotek Pharmaceuticals Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Inotek Pharmaceuticals Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Inotek Pharmaceuticals Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Inotek Pharmaceuticals Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Inotek Pharmaceuticals Corporation's pipeline products

Reasons to buy

  • Evaluate Inotek Pharmaceuticals Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Inotek Pharmaceuticals Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Inotek Pharmaceuticals Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Inotek Pharmaceuticals Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Inotek Pharmaceuticals Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Inotek Pharmaceuticals Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Inotek Pharmaceuticals Corporation Snapshot
  • Inotek Pharmaceuticals Corporation Overview
    • Key Information
    • Key Facts
  • Inotek Pharmaceuticals Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Inotek Pharmaceuticals Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Inotek Pharmaceuticals Corporation - Pipeline Products Glance
    • Inotek Pharmaceuticals Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Inotek Pharmaceuticals Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Inotek Pharmaceuticals Corporation - Drug Profiles
    • trabodenoson
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-4885
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-741
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INO-763
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PARP
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Inotek Pharmaceuticals Corporation - Pipeline Analysis
    • Inotek Pharmaceuticals Corporation - Pipeline Products by Target
    • Inotek Pharmaceuticals Corporation - Pipeline Products by Route of Administration
    • Inotek Pharmaceuticals Corporation - Pipeline Products by Molecule Type
    • Inotek Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action
  • Inotek Pharmaceuticals Corporation - Recent Pipeline Updates
  • Inotek Pharmaceuticals Corporation - Dormant Projects
  • Inotek Pharmaceuticals Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • PJ-34
  • Inotek Pharmaceuticals Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Inotek Pharmaceuticals Corporation, Key Information
  • Inotek Pharmaceuticals Corporation, Key Facts
  • Inotek Pharmaceuticals Corporation - Pipeline by Indication, 2014
  • Inotek Pharmaceuticals Corporation - Pipeline by Stage of Development, 2014
  • Inotek Pharmaceuticals Corporation - Monotherapy Products in Pipeline, 2014
  • Inotek Pharmaceuticals Corporation - Phase II, 2014
  • Inotek Pharmaceuticals Corporation - Phase I, 2014
  • Inotek Pharmaceuticals Corporation - Preclinical, 2014
  • Inotek Pharmaceuticals Corporation - Pipeline by Target, 2014
  • Inotek Pharmaceuticals Corporation - Pipeline by Route of Administration, 2014
  • Inotek Pharmaceuticals Corporation - Pipeline by Molecule Type, 2014
  • Inotek Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action, 2014
  • Inotek Pharmaceuticals Corporation - Recent Pipeline Updates, 2014
  • Inotek Pharmaceuticals Corporation - Dormant Developmental Projects,2014
  • Inotek Pharmaceuticals Corporation - Discontinued Pipeline Products, 2014

List of Figures

  • Inotek Pharmaceuticals Corporation - Pipeline by Top 10 Indication, 2014
  • Inotek Pharmaceuticals Corporation - Pipeline by Stage of Development, 2014
  • Inotek Pharmaceuticals Corporation - Monotherapy Products in Pipeline, 2014
  • Inotek Pharmaceuticals Corporation - Pipeline by Top 10 Target, 2014
  • Inotek Pharmaceuticals Corporation - Pipeline by Top 10 Route of Administration, 2014
  • Inotek Pharmaceuticals Corporation - Pipeline by Top 10 Molecule Type, 2014
  • Inotek Pharmaceuticals Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top